JonesTrading Downgrades Arcutis Biotherapeutics to Hold
Portfolio Pulse from Benzinga Newsdesk
JonesTrading analyst Sean Kim has downgraded Arcutis Biotherapeutics (NASDAQ:ARQT) from Buy to Hold.
November 08, 2023 | 10:22 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arcutis Biotherapeutics has been downgraded from Buy to Hold by JonesTrading.
The downgrade from Buy to Hold by JonesTrading indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in demand for the stock, and subsequently, a decrease in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100